Genomic BRCA and Extensive ovArian Cancer Testing (GREAT)

ARCAGY/ GINECO GROUP

Status: Completed

Conditions: Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04027868

GINECO-OV128

19.06.45 (Other Identifier)

2019-A01190-57 (Other Identifier)

Details and patient eligibility

About

This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

Full description

This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

Enrollment: 1,500 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient older than 18 years.

• Patient with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014)

• Patient in first line therapy

• Available tumor sample fixed in formalin and included in paraffin (FFPE):

  • in pre-chemotherapy, insofar as possible
  • having a sufficient tumor surface, with a final cellularity of at least 20%

• Identification of a molecular genetics' cancer platform participant in GREAT and an onco-geneticists team working with the investigator team

• Patient consenting her data to be collected and submitted through an automated processing

• Patient beneficiary from the French social security

Exclusion criteria

• Patient with a mucinous ovarian carcinoma
• Patient pregnant or breastfeeding
• Patient under legal protection (guardianship or court order) or unable to consent